Monday, August 20, 2018 1:37:54 AM
Viking Therapeutics, Inc. (NASDAQ: VKTX) is losing money like it's going out of style. The biotech's total revenue this year matches its total revenue last year -- zip, zero, nada. At best, Viking is still several years away from even possibly winning approval for its first drug.
So if you ask me whether or not Viking Therapeutics stock is a buy, my answer is an enthusiastic... "yes."
That's my answer, at least, for aggressive investors. Despite all of the negatives that I ticked off for Viking, I really like this stock as a speculative play.
Similar drugs, very different valuations
The biggest reason why I think so highly of Viking Therapeutics' prospects is that I also think highly of Madrigal Pharmaceuticals' (NASDAQ: MDGL) prospects. In May, Madrigal announced really good results from a phase 2 clinical study of its lead candidate MGL-3196 in treating non-alcoholic steatohepatitis (NASH).
MGL-3196 met its primary endpoint of a statistically significant reduction of liver fat. Researchers use the probability value, or p-value, to determine whether a result was statistically significant. A p-value of less than 0.05 is the standard threshold they seek. MGL-3196 achieved a p-value of less than 0.0001. As icing on the cake, the drug also hit all of the study's key secondary endpoints. And it did all of this with a pretty good safety profile.
What does all of this have to do with Viking? The biotech also has a pipeline candidate, VK2809, that's still in a phase 2 clinical study targeting treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL cholesterol. NASH, by the way, is a serious type of NAFLD. Here's the important thing to know: Both MGL-3196 and VK2809 are thyroid hormone receptor (THR) beta-selective agonists.
Now, it's possible that Viking's drug won't be as effective as Madrigal's. However, I think there's a pretty good chance that VK2809 will be successful in its phase 2 study. We won't know for sure, though, until Viking announces the results from the study later this year.
In the meantime, Madrigal claims a market cap of $3.7 billion compared to Viking's market cap of around $640 million. The difference in the two biotechs' valuations is big primarily because of the possibility that VK2809's results will be disappointing. But if Viking reports positive results for the drug in a few months, the gap between its market cap and Madrigal's will narrow significantly.
An attractive acquisition target
In June, I listed Madrigal and Viking as the two top takeover targets in the NASH space. I still think both biotechs are likely to be on the radar screens for bigger players.
I'm actually rooting for Gilead Sciences (NASDAQ: GILD) to buy either Madrigal or Viking and for Pfizer (NYSE: PFE) to scoop up whichever one Gilead doesn't acquire. Why? I own positions in both Gilead and Pfizer and would love to see them succeed in the NASH market.
Gilead would be a great suitor for Viking for a couple of reasons. First, the big biotech is already a leader in NASH with three candidates in its pipeline. Based on what I've read and heard from scientists who are experts in NASH, I suspect that combination therapies will be most effective in treating the disease. Adding a THR beta-selective agonist in the mix with its ASK-1 inhibitor, ACC inhibitor, and FXR agonist could be just the ticket for Gilead to become a major winner in the NASH market.
The second reason I think Gilead is an ideal company to buy Viking is that it has plenty of money to spend. As of the end of June, Gilead claimed $31.7 billion in cash, cash equivalents, and marketable securities. It could buy Viking with its spare change.
Pfizer isn't quite as far along as Gilead is. The big pharma company has a couple of NASH candidates in phase 2 testing with another experimental drug in phase 1. None of these drugs have the same mechanism of action as VK2809, so Viking's drug could be a good addition to Pfizer's pipeline. Pfizer isn't hurting for cash to spend on a small acquisition, either, with the company reporting $13.4 billion in cash, cash equivalents, and short-term investments as of the end of June.
Adding it all up
As I pointed out, there are plenty of reasons to avoid Viking Therapeutics stock. However, I think the risk-reward proposition for the stock looks pretty good.
All Viking needs is successful results in its phase 2 study of VK2809. Based on historical data, there's a 45% probability that a metabolic drug in phase 2 testing will have positive results and advance to a phase 3 clinical study. I think the previous results for Madrigal's similar drug gives VK2809 even better odds than that.
If I'm right and Viking announces solid phase 2 results in a few months, the biotech's share price will soar. And I suspect that one or more big players looking to pick up a promising NASH candidate will come calling. Aggressive investors should like those prospects.
https://finance.yahoo.com/news/viking-therapeutics-inc-buy-130200243.html
GO MDGL
"PEACE"
Recent MDGL News
- Madrigal Statement on the Passing of Dr. Stephen Harrison • GlobeNewswire Inc. • 04/24/2024 08:00:00 PM
- Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/16/2024 08:05:00 PM
- Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/03/2024 08:05:00 PM
- Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering • GlobeNewswire Inc. • 03/19/2024 03:58:56 AM
- Madrigal Pharmaceuticals Announces Proposed Public Offering • GlobeNewswire Inc. • 03/18/2024 08:04:05 PM
- Adobe Stock Drops Following Below-Estimate Projections, Cardlytics Surges with Unexpected Profit, and More News • IH Market News • 03/15/2024 11:30:55 AM
- Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis • GlobeNewswire Inc. • 03/14/2024 08:15:00 PM
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/06/2024 09:05:00 PM
- Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:01:31 PM
- Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer • GlobeNewswire Inc. • 02/28/2024 12:01:00 PM
- Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/28/2024 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 11:32:35 AM
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/21/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:50:08 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:21:37 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 10:55:57 PM
- Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/06/2024 09:05:00 PM
- Madrigal Pharmaceuticals Announces Additions to Its Leadership Team • GlobeNewswire Inc. • 01/29/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 11:04:23 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM